Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and A β42/40 ratio to identify presence of brain amyloid

DISCUSSION: The PrecivityAD2 blood test showed strong clinical validity, with excellent agreement with brain amyloidosis by PET.PMID:38491912 | DOI:10.1002/alz.13764

Source: The Journal of Alzheimers Association - March 16, 2024 Category: Psychiatry Authors: Matthew R Meyer Kristopher M Kirmess Stephanie Eastwood Traci L Wente-Roth Faith Irvin Mary S Holubasch Venky Venkatesh Ilana Fogelman Mark Monane Lucy Hanna Gil D Rabinovici Barry A Siegel Rachel A Whitmer Charles Apgar Randall J Bateman David M Holtzman Source Type: research